RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Diamyd Medical ROE 2024

Diamyd Medical ROE

-0.69

Diamyd Medical Dividend yield

Ticker

DMYD B.ST

ISIN

SE0005162880

WKN

A1T90L

In 2024, Diamyd Medical's return on equity (ROE) was -0.69, a 41.9% increase from the -0.48 ROE in the previous year.

Diamyd Medical Aktienanalyse

What does Diamyd Medical do?

Diamyd Medical AB is a Swedish company specializing in the development of therapies for the treatment of autoimmune diseases, particularly type 1 diabetes. The company was founded in 1996 and is headquartered in Stockholm. It commercialized the discovery of Professor Johnny Ludvigsson at Linköping University, who developed a therapy based on the substance GAD (Glutamate Decarboxylase). The company has developed its own GAD-based product called Diamyd®, which is an injection solution that targets the patient's immune system to protect insulin production. In addition to Diamyd®, the company has developed other products based on similar active ingredients, the most important being Remygen®, which combines insulin and GAD to promote insulin production. Diamyd Medical has a broad portfolio of patents and licenses to protect its intellectual property and improve its technologies. The company collaborates closely with other researchers and industry stakeholders to develop and test new therapeutic approaches. Its business model involves licensing its products to pharmaceutical companies and other partners, who then assume responsibility for clinical development and marketing while Diamyd Medical focuses on research and development of new products. The company has expanded into other areas of medicine, including cancer immunotherapy, neurology, and cell therapy. It is currently working on a promising new technology that utilizes Treg cells (regulatory T cells) for the treatment of autoimmune diseases. Diamyd Medical is well-positioned to further expand its market position and drive the development of new therapies. Diamyd Medical ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Diamyd Medical's Return on Equity (ROE)

Diamyd Medical's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Diamyd Medical's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Diamyd Medical's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Diamyd Medical’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Diamyd Medical Stock

What is the ROE (Return on Equity) of Diamyd Medical this year?

The ROE of Diamyd Medical this year is -0.69 undefined.

How has the Return on Equity (ROE) of Diamyd Medical developed compared to the previous year?

The ROE of Diamyd Medical has increased by 41.9% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Diamyd Medical?

A high ROE indicates that Diamyd Medical generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Diamyd Medical?

A low ROE can indicate that Diamyd Medical is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Diamyd Medical affect the company?

A change in ROE (Return on Equity) of Diamyd Medical can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Diamyd Medical?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Diamyd Medical?

Some factors that can influence Diamyd Medical's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Diamyd Medical pay?

Over the past 12 months, Diamyd Medical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Diamyd Medical is expected to pay a dividend of 0 SEK.

What is the dividend yield of Diamyd Medical?

The current dividend yield of Diamyd Medical is .

When does Diamyd Medical pay dividends?

Diamyd Medical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Diamyd Medical?

Diamyd Medical paid dividends every year for the past 0 years.

What is the dividend of Diamyd Medical?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Diamyd Medical located?

Diamyd Medical is assigned to the 'Health' sector.

Wann musste ich die Aktien von Diamyd Medical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Diamyd Medical from 5/23/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 5/23/2024.

When did Diamyd Medical pay the last dividend?

The last dividend was paid out on 5/23/2024.

What was the dividend of Diamyd Medical in the year 2023?

In the year 2023, Diamyd Medical distributed 0 SEK as dividends.

In which currency does Diamyd Medical pay out the dividend?

The dividends of Diamyd Medical are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Diamyd Medical

Our stock analysis for Diamyd Medical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Diamyd Medical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.